DON LYNN GIBBONS to Antineoplastic Agents
This is a "connection" page, showing publications DON LYNN GIBBONS has written about Antineoplastic Agents.
Connection Strength
0.315
-
The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm. Cancer. 2012 Jan 15; 118(2):293-9.
Score: 0.078
-
Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors. Mol Cancer Ther. 2024 Aug 01; 23(8):1144-1158.
Score: 0.048
-
Directions to overcome therapy resistance in cancer. Trends Pharmacol Sci. 2024 Jun; 45(6):467-471.
Score: 0.048
-
Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC. J Thorac Oncol. 2024 03; 19(3):500-506.
Score: 0.046
-
A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components. Sci Transl Med. 2020 09 02; 12(559).
Score: 0.037
-
TMEM106B drives lung cancer metastasis by inducing TFEB-dependent lysosome synthesis and secretion of cathepsins. Nat Commun. 2018 07 16; 9(1):2731.
Score: 0.032
-
Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma. Clin Cancer Res. 2016 07 15; 22(14):3630-42.
Score: 0.027